Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855465 | 0.82 | APLNR (0.38) | APLNR | |
| SCHEMBL13732902 | 0.81 | APLNR (0.41) | APLNR | |
| SCHEMBL21123498 | 0.78 | APLNR (0.35) | APLNR | |
| SCHEMBL21855470 | 0.77 | APLNR (0.34) | APLNR | |
| SCHEMBL23415526 | 0.76 | APLNR (0.41) | APLNR | |
| SCHEMBL25167860 | 0.75 | APLNR (0.38) | APLNR | |
| SCHEMBL15339551 | 0.74 | APLNR (0.39) | APLNR | |
| SCHEMBL28838661 | 0.72 | APLNR (0.34) | APLNR | |
| SCHEMBL25139132 | 0.71 | APLNR (0.37) | APLNR | |
| SCHEMBL19814825 | 0.71 | APLNR (0.37) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2022119899-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN | SHIONOGI & CO., LTD. (JP) | 2022-06-09 | — | — | WO | disclosed |
| US-20220009912-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | Adaris Therapeutics, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | APLNR 2896/4885 |
| US-11820759-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | APLNR 211/4885 |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | APLNR 2896/4885 |
| US-20220009912-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CCR5, CXCR3, CCR2 | APLNR 211/4885 |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | APLNR 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.